Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Kymera Therapeutics Ownership Summary

Kymera Therapeutics is owned by 27.69% institutional investors, 2.70% insiders, and 69.62% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.70% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Kymera Therapeutics	27.69%	2.70%	69.62%
Sector	Healthcare Stocks	279.18%	10.62%	-189.80%
Industry	Biotech Stocks	63.96%	10.74%	25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Price t rowe associates inc /md/	6.87M	9.03%	$276.39M
Avoro capital advisors	6.46M	8.06%	$176.81M
Baker bros. advisors lp	6.00M	7.48%	$164.11M
Wellington management group llp	5.31M	6.97%	$213.51M
Bvf inc/il	5.16M	6.44%	$141.28M
Atlas venture life science advisors	4.90M	6.43%	$196.98M
Vanguard group	4.89M	6.42%	$196.62M
Fmr	4.83M	6.35%	$194.33M
Blackrock	4.16M	5.87%	$124.04M
Blackrock funding, inc. /de	4.36M	5.72%	$175.25M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Atlas venture life science advisors	4.90M	24.03%	$196.98M
Merck	772.16K	12.04%	$31.06M
Aquilo capital management	138.52K	6.80%	$3.79M
Bvf inc/il	5.16M	5.76%	$141.28M
Siren	2.97M	5.28%	$119.47M
Avoro capital advisors	6.46M	2.76%	$176.81M
Redmile group	983.41K	2.54%	$26.92M
Artal group	3.01M	2.29%	$89.72M
Foresite capital management vi	146.33K	2.19%	$4.01M
Checkpoint capital	136.60K	2.05%	$3.74M

Top Buyers

Holder	Shares	% Assets	Change
Avoro capital advisors	6.46M	2.76%	1.31M
Merck	772.16K	12.04%	772.16K
Wellington management group llp	5.31M	0.04%	688.97K
Blackrock	4.16M	0.00%	499.77K
Millennium management	510.48K	0.01%	394.56K

Top Sellers

Holder	Shares	% Assets	Change
Deep track capital, lp	-	-	-600.33K
Avidity partners management lp	-	-	-500.00K
First light asset management	-	-	-383.31K
Ecor1 capital	-	-	-350.00K
Fmr	4.83M	0.01%	-278.72K

New Positions

Holder	Shares	% Assets	Change	Value
Merck	772.16K	12.04%	772.16K	$31.06M
Patient square capital lp	142.20K	1.61%	142.20K	$3.89M
Norges bank	91.23K	0.00%	91.23K	$3.67M
Exoduspoint capital management, lp	14.13K	0.00%	14.13K	$568.00K
Peak6 investments	13.00K	0.00%	13.00K	$388.05K

Sold Out

Holder	Change
Financial gravity asset management	-2.00
Capital performance advisors llp	-3.00
Riggs asset managment	-7.00
Nelson, van denburg & campbell wealth management group	-8.00
Cva family office	-12.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	20	-89.07%	22,191,205	-69.06%	27	0.31%	7	-92.39%	4	-93.10%
Dec 31, 2024	180	-0.55%	71,156,642	3.18%	93	1.14%	88	-4.35%	59	-4.84%
Sep 30, 2024	181	16.03%	68,964,551	2.37%	90	1.00%	93	6.90%	62	31.91%
Jun 30, 2024	155	-4.32%	67,367,833	0.44%	95	0.72%	86	-14.85%	47	11.90%
Mar 31, 2024	162	20.00%	67,073,034	11.04%	114	1.07%	101	48.53%	42	-17.65%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
US Small-Cap Growth II Equity Comp	3.05M	4.70%	-42.16K
T. Rowe Price New Horizons	3.05M	4.70%	-41.27K
Vanguard Health Care Inv	3.01M	4.63%	662.16K
Fidelity Growth Compy Commingled Pl O	2.24M	3.46%	52.60K
Fidelity Growth Compy Commingled Pl S	1.95M	2.99%	18.30K
Vanguard Total Stock Mkt Idx Inv	1.78M	2.74%	9.17K
Vanguard US Total Market Shares ETF	1.54M	2.38%	1.91K
Vanguard Small Cap Index	1.39M	2.13%	6.08K
Fidelity Growth Company Fund	1.35M	2.07%	3.40K
T. Rowe Price Health Sciences	1.21M	1.86%	19.81K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 11, 2025	Ridloff Elena	-	Sell	$225.00K
Jun 03, 2025	Esposito Pamela	-	Sell	$245.19K
Jun 03, 2025	Ridloff Elena	-	Sell	$327.60K
Jun 03, 2025	Ridloff Elena	-	Sell	$225.60K
Jun 03, 2025	Mainolfi Nello	Chief Executive Officer	Sell	$1.47M

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	7
2025 Q1	-	9
2024 Q4	-	1
2024 Q3	5	16
2024 Q2	-	9

KYMR Ownership FAQ

Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 27.69%, followed by 2.70% insiders and 69.61% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 63.96%, which Kymera Therapeutics falls below.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (6.87M shares, 9.03%), Avoro capital advisors (6.46M shares, 8.06%), and Baker bros. advisors lp (6M shares, 7.48%). Together, they hold 24.57% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 24.03% of its assets in 4.9M Kymera Therapeutics shares, valued at 196.98M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Kymera Therapeutics shares, with 4.70% of its total shares outstanding invested in 3.05M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools